Summary
Unable to assess alignment with the supplied FDA-approved label excerpts because the provided prescribing information contains only fetal toxicity/pregnancy risk text, while the AI claims concern kidney function, potassium, monitoring, and management in heart failure patients—none of which are supported or contradicted by the provided label excerpts.
Category Scores
Accurate Statements
Unsupported Statements
Entresto (sacubitril/valsartan) can affect kidney function by changing how the kidneys filter blood.
Not supported by the provided label excerpts (only fetal toxicity/pregnancy information was supplied).
Clinicians monitor kidney function and potassium levels after starting or adjusting Entresto because worsening labs can occur in some patients.
Not supported by the provided label excerpts.
Entresto is associated with increases in serum creatinine.
Not supported by the provided label excerpts.
Entresto can be associated with higher serum potassium.
Not supported by the provided label excerpts.
Patients with chronic kidney disease are more likely to experience concerning kidney laboratory changes on Entresto.
Not supported by the provided label excerpts.
People with heart failure with reduced ejection fraction are more likely to experience concerning kidney laboratory changes on Entresto.
Not supported by the provided label excerpts.
Entresto can increase serum potassium and creatinine particularly in people who take other drugs that affect the renin-angiotensin-aldosterone system (RAAS) or potassium.
Not supported by the provided label excerpts.
Serum creatinine is used as a proxy for changes in kidney filtration when assessing kidney effects of Entresto.
Not supported by the provided label excerpts.
eGFR is one of the measures clinicians use to assess kidney effects of Entresto.
Not supported by the provided label excerpts.
Serum potassium is monitored due to the risk of hyperkalemia related to RAAS pathway drugs, including valsartan (a component of Entresto).
Not supported by the provided label excerpts.
If creatinine rises after starting or up-titrating Entresto, clinicians may reduce the dose, pause therapy, or adjust interacting medications and dietary potassium depending on severity.
Not supported by the provided label excerpts.
If potassium increases after starting or up-titrating Entresto, clinicians may reduce the dose, pause therapy, or adjust interacting medications and dietary potassium depending on severity.
Not supported by the provided label excerpts.
Pre-existing chronic kidney disease increases the likelihood of concerning kidney lab changes with Entresto.
Not supported by the provided label excerpts.
Higher baseline potassium increases the likelihood of concerning kidney lab changes with Entresto.
Not supported by the provided label excerpts.
Dehydration or low blood pressure increases the likelihood of concerning kidney lab changes with Entresto.
Not supported by the provided label excerpts.
Renal artery disease or other conditions that make renal perfusion more fragile increases the likelihood of concerning kidney lab changes with Entresto.
Not supported by the provided label excerpts.
Use of other medications that can raise potassium or affect kidney filtration increases the likelihood of concerning kidney lab changes with Entresto.
Not supported by the provided label excerpts.
The response mentions RAAS inhibitors and certain diuretics as examples of medications that can contribute to hyperkalemia and affect kidney filtration in patients taking Entresto.
Not supported by the provided label excerpts.
Patients should not stop Entresto on their own if kidney numbers rise after starting it.
Not supported by the provided label excerpts.
Prompt lab monitoring of creatinine/eGFR and potassium is recommended after initiation and after dose changes of Entresto.
Not supported by the provided label excerpts.
Clinicians adjust medications based on the trend and degree of change in kidney function and potassium labs after starting or changing Entresto.
Not supported by the provided label excerpts.
A small creatinine rise can sometimes occur after starting RAAS-targeting therapy.
Not supported by the provided label excerpts.
Clinicians evaluate the size and speed of creatinine change and overall clinical status (blood pressure, fluid status, symptoms) when a creatinine rise occurs on RAAS-targeting therapy.
Not supported by the provided label excerpts.
Worsening kidney laboratory values can coexist with better cardiovascular outcomes from RAAS-related therapies.
Not supported by the provided label excerpts.
The clinical approach is to balance kidney lab changes against heart-failure benefit and manage modifiable contributors (volume status, interacting drugs, potassium intake) while continuing or adjusting Entresto as appropriate.
Not supported by the provided label excerpts.
Entresto may be associated with symptoms that could align with high potassium, such as marked weakness, palpitations, or muscle symptoms.
Not supported by the provided label excerpts.
Seek urgent medical care if there is severe worsening shortness of breath, dizziness/fainting, or very low blood pressure.
Not supported by the provided label excerpts.
Entresto can worsen kidney function by raising serum creatinine and serum potassium in some patients.
Not supported by the provided label excerpts.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
The provided label excerpts do not include sections covering kidney function, potassium/hyperkalemia, monitoring, dosing adjustments, drug interactions, or adverse reactions related to renal labs. Therefore, the AI claims regarding these topics cannot be evaluated against the supplied label content.
Importance:
High
Safety Assessment
Potential Patient Risk:
Unknown
The AI-generated claims contain multiple kidney/potassium monitoring and management recommendations, but the supplied prescribing information excerpts do not address these topics. As a result, the risk of incorrect or unsupported clinical guidance cannot be determined from the provided label material.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Verifiable with Provided Label
Primary Issue
Only fetal toxicity/pregnancy excerpts were provided; none of the kidney function/potassium/monitoring content required to verify the claims is present.
Suggested Improvement
Provide the relevant Entresto label sections (e.g., Warnings/Precautions, Drug Interactions, Adverse Reactions, Dosage/Administration, and any specific monitoring guidance) that discuss renal function and serum potassium/hyperkalemia so the claims can be evaluated accurately.